Metformina Pensa (Metformin Hydrochloride)

Metformin primarily inhibits mitochondrial respiratory‑chain complex I, which reduces hepatic gluconeogenesis. It also enhances peripheral glucose uptake in muscle and adipose tissue and improves insulin signaling pathways. The combined effect lowers fasting and post‑prandial blood glucose without stimulating insulin secretion, reducing the risk of hypoglycemia when used alone.

The specific dose of Metformina Pensa is determined by the prescribing clinician based on individual factors such as baseline glycemic control, renal function, and concomitant medications. The prescriber will select an appropriate starting dose and titrate as needed to achieve therapeutic goals while monitoring safety parameters.

The safety of metformin during pregnancy and lactation has not been definitively established, and it is classified as pregnancy category unknown. Clinicians must weigh potential benefits against risks, and use it only if clearly needed. Breastfeeding mothers should consult their healthcare provider, as metformin is excreted in small amounts in breast milk.

To place an order, submit an enquiry on the Metformina Pensa product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature requirements), and necessary import documentation.

Compared with sulfonylureas, metformin does not stimulate insulin secretion, resulting in a lower risk of hypoglycemia. Unlike insulin therapy, it is administered orally and does not require injection. Its weight‑neutral or modest weight‑loss effect contrasts with the weight gain often seen with thiazolidinediones, making it a first‑line option for many patients.

Metformina Pensa should be stored at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or near heat sources. Do not use if the packaging is damaged or the tablets appear discolored.

Metformina Pensa is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a glass of water and not crushed or chewed. Patients should follow the dosing schedule prescribed by their healthcare professional and attend regular follow‑up appointments to monitor blood glucose and renal function.

The most serious adverse reactions include lactic acidosis, a rare but potentially fatal metabolic disturbance, and severe hypoglycemia when combined with other glucose‑lowering agents. Early signs such as unexplained fatigue, abdominal pain, rapid breathing, or muscle weakness require immediate medical attention. Regular monitoring of renal function helps mitigate these risks.

Metformina Pensa is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, including diabetic ketoacidosis, and those receiving radiographic contrast studies that may affect kidney function. Clinicians should also exercise caution in individuals with significant hepatic disease or heart failure.